INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment

M. J. Brown, A. Castaigne, L. M. Ruilope, G. Mancia, T. Rosenthal, P. W. De Leeuw, F. Ebner

Research output: Contribution to journalArticle

Abstract

The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide. A total of 6592 patients from nine countries (UK, France, Israel, Spain, Italy, The Netherlands, Sweden, Denmark and Norway) will be recruited, aged 55-80 and with a blood pressure (BP) ≤ 150/95 or ≤ 160 mmHg (systolic). All patients will have at least one other major cardiovascular risk factor. Patients will be minimised by country and risk factors and randomised to double-blind treatment with either nifedipine GITS or diuretic. After a single dose titration, additional treatment will be atenolol or enalapril (where P-blockade is contra-indicated). After achieving a target BP of 140/90 mmHg patients will be followed for a total of 3 years. Primary endpoints are myocardial infarction, stroke, subarachnoid haemorrhage, heart failure and sudden cardiac death. The study has a power of 80% at 5% significance to detect a difference between 8% event rate over 3 years in diuretic-treated patients and 6% in those receiving nifedipine.

Original languageEnglish
JournalJournal of Human Hypertension
Volume10
Issue numberSUPPL. 3
Publication statusPublished - 1996

Fingerprint

Nifedipine
Hypertension
Diuretics
Therapeutics
Blood Pressure
Sodium Chloride Symporter Inhibitors
Enalapril
Atenolol
Sudden Cardiac Death
Calcium Channel Blockers
Israel
Subarachnoid Hemorrhage
Denmark
Norway
Sweden
Netherlands
Spain
Italy
France
Heart Failure

Keywords

  • Morbidity
  • Mortality
  • Nifedipine
  • Outcome trial
  • Thiazide

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Brown, M. J., Castaigne, A., Ruilope, L. M., Mancia, G., Rosenthal, T., De Leeuw, P. W., & Ebner, F. (1996). INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. Journal of Human Hypertension, 10(SUPPL. 3).

INSIGHT : International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. / Brown, M. J.; Castaigne, A.; Ruilope, L. M.; Mancia, G.; Rosenthal, T.; De Leeuw, P. W.; Ebner, F.

In: Journal of Human Hypertension, Vol. 10, No. SUPPL. 3, 1996.

Research output: Contribution to journalArticle

Brown, MJ, Castaigne, A, Ruilope, LM, Mancia, G, Rosenthal, T, De Leeuw, PW & Ebner, F 1996, 'INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment', Journal of Human Hypertension, vol. 10, no. SUPPL. 3.
Brown MJ, Castaigne A, Ruilope LM, Mancia G, Rosenthal T, De Leeuw PW et al. INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. Journal of Human Hypertension. 1996;10(SUPPL. 3).
Brown, M. J. ; Castaigne, A. ; Ruilope, L. M. ; Mancia, G. ; Rosenthal, T. ; De Leeuw, P. W. ; Ebner, F. / INSIGHT : International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. In: Journal of Human Hypertension. 1996 ; Vol. 10, No. SUPPL. 3.
@article{b72a83fa501e4fb8a3a6c8b4b2a46f29,
title = "INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment",
abstract = "The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide. A total of 6592 patients from nine countries (UK, France, Israel, Spain, Italy, The Netherlands, Sweden, Denmark and Norway) will be recruited, aged 55-80 and with a blood pressure (BP) ≤ 150/95 or ≤ 160 mmHg (systolic). All patients will have at least one other major cardiovascular risk factor. Patients will be minimised by country and risk factors and randomised to double-blind treatment with either nifedipine GITS or diuretic. After a single dose titration, additional treatment will be atenolol or enalapril (where P-blockade is contra-indicated). After achieving a target BP of 140/90 mmHg patients will be followed for a total of 3 years. Primary endpoints are myocardial infarction, stroke, subarachnoid haemorrhage, heart failure and sudden cardiac death. The study has a power of 80{\%} at 5{\%} significance to detect a difference between 8{\%} event rate over 3 years in diuretic-treated patients and 6{\%} in those receiving nifedipine.",
keywords = "Morbidity, Mortality, Nifedipine, Outcome trial, Thiazide",
author = "Brown, {M. J.} and A. Castaigne and Ruilope, {L. M.} and G. Mancia and T. Rosenthal and {De Leeuw}, {P. W.} and F. Ebner",
year = "1996",
language = "English",
volume = "10",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - INSIGHT

T2 - International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment

AU - Brown, M. J.

AU - Castaigne, A.

AU - Ruilope, L. M.

AU - Mancia, G.

AU - Rosenthal, T.

AU - De Leeuw, P. W.

AU - Ebner, F.

PY - 1996

Y1 - 1996

N2 - The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide. A total of 6592 patients from nine countries (UK, France, Israel, Spain, Italy, The Netherlands, Sweden, Denmark and Norway) will be recruited, aged 55-80 and with a blood pressure (BP) ≤ 150/95 or ≤ 160 mmHg (systolic). All patients will have at least one other major cardiovascular risk factor. Patients will be minimised by country and risk factors and randomised to double-blind treatment with either nifedipine GITS or diuretic. After a single dose titration, additional treatment will be atenolol or enalapril (where P-blockade is contra-indicated). After achieving a target BP of 140/90 mmHg patients will be followed for a total of 3 years. Primary endpoints are myocardial infarction, stroke, subarachnoid haemorrhage, heart failure and sudden cardiac death. The study has a power of 80% at 5% significance to detect a difference between 8% event rate over 3 years in diuretic-treated patients and 6% in those receiving nifedipine.

AB - The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide. A total of 6592 patients from nine countries (UK, France, Israel, Spain, Italy, The Netherlands, Sweden, Denmark and Norway) will be recruited, aged 55-80 and with a blood pressure (BP) ≤ 150/95 or ≤ 160 mmHg (systolic). All patients will have at least one other major cardiovascular risk factor. Patients will be minimised by country and risk factors and randomised to double-blind treatment with either nifedipine GITS or diuretic. After a single dose titration, additional treatment will be atenolol or enalapril (where P-blockade is contra-indicated). After achieving a target BP of 140/90 mmHg patients will be followed for a total of 3 years. Primary endpoints are myocardial infarction, stroke, subarachnoid haemorrhage, heart failure and sudden cardiac death. The study has a power of 80% at 5% significance to detect a difference between 8% event rate over 3 years in diuretic-treated patients and 6% in those receiving nifedipine.

KW - Morbidity

KW - Mortality

KW - Nifedipine

KW - Outcome trial

KW - Thiazide

UR - http://www.scopus.com/inward/record.url?scp=0029745614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029745614&partnerID=8YFLogxK

M3 - Article

C2 - 8872850

AN - SCOPUS:0029745614

VL - 10

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - SUPPL. 3

ER -